Host thromboinflammatory pathways

Thromboinflammation refers to the complex reciprocal activation between the coagulation system and the innate immune system, where inflammatory mediators trigger thrombotic events and vice versa (Engelmann & Massberg, Nat Rev Immunol, 2013). In the context of venous thromboembolism (VTE), these pathways involve the activation of the contact system (Factors XI and XII), the release of neutrophil extracellular traps (NETs), and the expression of tissue factor on monocytes (Mackman et al., Nat Rev Cardiol, 2020). These processes create a prothrombotic environment that leads to deep vein thrombosis and pulmonary embolism, particularly during systemic inflammatory states such as sepsis, cancer, or COVID-19 (Stark & Massberg, Nat Rev Cardiol, 2021). Activated coagulation factors like thrombin and Factor Xa further amplify inflammation by signaling through protease-activated receptors (PARs) on endothelial cells and leukocytes. Therapeutic strategies targeting these pathways include traditional anticoagulants like Factor Xa inhibitors and newer agents targeting Factor XIa, which aim to decouple pathological thrombosis from physiological hemostasis (Fredenburgh & Weitz, J Thromb Haemost, 2021). Understanding these pathways is essential for developing precision therapies that mitigate thrombotic risk while minimizing the bleeding complications associated with current standard-of-care treatments.

Other names

ImmunothrombosisThromboinflammationCoagulation-inflammation crosstalkInflammatory-thrombotic circuit

Inhibition of coagulation factors (Factor Xa, Thrombin, Factor XIa), antagonism of protease-activated receptors (PARs), inhibition of neutrophil extracellular trap (NET) formation, and modulation of inflammatory cytokine signaling.